Sexually transmitted diseases最新文献

{"title":"Changes in providers diagnosing sexually transmitted infections in Louisiana, 2018-2024.","authors":"Mohammad M Rahman, River A Pugsley, Franda J Thomas, Nicole L Davis","doi":"10.1097/OLQ.0000000000002409","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002409","url":null,"abstract":"<p><strong>Background: </strong>Louisiana ranks high nationally for chlamydia (CT), gonorrhea (GC), and syphilis rates. During the COVID-19 pandemic, many providers operated with limited staff and business hours, potentially limiting access to routine sexually transmitted infection (STI) care. We evaluated changes in STI morbidity and provider types in Louisiana from March 2018 to February 2024.</p><p><strong>Methods: </strong>Using Louisiana surveillance data, we compared reported STI case counts by demographic characteristics and identified the type of healthcare providers diagnosing STIs before, during, and after COVID-19 pandemic. We calculated the percent change in case counts across time periods and assessed for differential shifts in the proportion of cases diagnosed by provider type.</p><p><strong>Results: </strong>The number of reported GC and syphilis cases increased pre- to post-COVID (by 8.7% and 62.5% respectively), while CT diagnoses nearly returned to pre-COVID levels (1% decrease). Sex, age and race/ethnicity of cases remained similar across time periods. The proportion of STIs diagnosed by private providers increased pre- to post-COVID: 75% to 82.2% of CT; 74.5% to 82.9% of GC; and 66.1% to 77.3 % of syphilis cases. There was a corresponding decrease in the proportion of cases diagnosed by public providers. Specifically, the proportion of cases diagnosed by private clinics, hospitals, and urgent care increased; the proportion of cases diagnosed by parish health units decreased.</p><p><strong>Conclusions: </strong>Reported STI case counts in Louisiana have increased since COVID, and we observed a notable increase in the proportion diagnosed by private providers. Outreach efforts may be needed to reach cases diagnosed outside of traditional sexual health care settings.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Actually, that's one of the reasons I stopped getting tested often, because I didn't want to be judged:\" Sexual Healthcare and STI Testing Experiences Among U.S. Men Who Have Sex With Men.","authors":"Christopher T Georgas, Jacob Bleasdale, Gayathri Kothawar, Ansley Bravo, Jamie Pomeranz, Viraj V Patel, Jacqueline Sherbuk, Christian Grov, Drew A Westmoreland","doi":"10.1097/OLQ.0000000000002411","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002411","url":null,"abstract":"<p><strong>Background: </strong>Men who have sex with men (MSM) havea high need for sexual healthcare, but often report experiences of stigma and discrimination in sexual healthcare-seeking interactions. This qualitative analysis describes experiences of MSM seeking sexual healthcare, as well as barriers and facilitators to engaging in sexual healthcare.</p><p><strong>Methods: </strong>Data were collected from June to September 2024 as part of a cross-sectional, mixed methods study exploring the acceptability and use of doxycycline post-exposure prophylaxis (doxy-PEP). One-on-one, semi-structured interviews were conducted (via Zoom) followed by a brief online quantitative survey. Interviews were audio-recorded, transcribed verbatim, and thematically analyzed.</p><p><strong>Results: </strong>Participants had a median age of 35 (IQR = 30-38), and most had at least a four-year college degree (59%). Fifty-two percent identified as White, 24% identified as Latino, 10% identified as Black/African American, and 14% identified as another race or ethnicity. Participants described positive sexual healthcare experiences including LGBTQ-focused care and personable staff. Concerns with seeking sexual healthcare were prevalent, including lack of provider knowledge, interpersonal staff concerns, and judgment. Participants described how free testing and accessible services served as facilitators to STI testing, whereas insurance complexities and unreliable transportation were identified as barriers.</p><p><strong>Conclusion: </strong>Improving culturally sensitive and relevant healthcare for MSM may improve engagement and provide increased opportunities for HIV and STI prevention.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evaluation of post-sexual assault care guidelines using the AGREE II toolkit with a focus on prophylactic antibiotic recommendations.","authors":"Clare Lewandowski-Fowler-Porter, Jarlath Swail, Abir Mamun, Georgia Horsman, Clare Taverner, Daniel Richardson, Suneeta Soni","doi":"10.1097/OLQ.0000000000002399","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002399","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate nationally and internationally published, English-language clinical guidelines on the management of sexual assault, with a specific focus on the recommendations for antimicrobial prophylaxis for sexually transmitted infections, using the AGREE II toolkit and a bespoke assessment framework co-designed with survivors.</p><p><strong>Method: </strong>A comprehensive online search (Google, SAFEta, the TRIP database, and UpToDate) for clinical guidelines published in the past five years was performed and reported using the PRISMA guidelines. Four reviewers independently appraised each guideline using the appraisal of guidelines for research and evaluation (AGREE II) tool. An AGREE II domain score of >60% is the threshold for sufficient quality, and each guideline was rated high, average or low based on the domain percentages (five domains scoring >60%=high, 3-4 domains scoring >60%=average and ≤2 domains scoring>60%=low). A bespoke evaluation tool, developed with survivors, was applied to assess inclusive language, clarity of antimicrobial prophylaxis criteria, adherence considerations, antimicrobial stewardship, psychological impact, and follow-up guidance.</p><p><strong>Results: </strong>Sixteen guidelines met inclusion criteria from the WHO, UK, USA, Ireland and Australia. The median overall AGREE II score was 65% (IQR 42-79). The overall AGREE II score was 69% (IQR 45-81) (domain 1 (scope and purpose) 89% (IQR=80-92), domain 2 (stakeholder involvement) 75% (IQR=68-76), domain 3 (rigour of development) 42% (IQR=32-57), domain 4 (clarity of presentation) 80% (IQR=72-85), domain 5 (applicability) 56% (IQR 48=63), domain 6 (editorial independence) 69% (IQR=45-81)). Three guidelines (WHO, BASHH-UK, CDC: USA) had a high overall rating and overall scores of 6. Six guidelines met all bespoke tool criteria: BASHH, CDC, Wales, USA, Scotland, and WHO.</p><p><strong>Conclusion: </strong>Future guideline development should prioritise editorial independence, developmental rigour, and applicability.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Really just recognizing that women also have sex.\": A qualitative analysis of cisgender women's self-reported barriers to accessing PrEP.","authors":"Rey Flores, Alison Goldberg, Taiylar Ball, Arielle Desir, Jonathan Purtle, Don Operario, Jennifer Pellowski, Devon Price","doi":"10.1097/OLQ.0000000000002416","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002416","url":null,"abstract":"<p><strong>Background: </strong>Cisgender women (hereafter, referred to as women) account for approximately 19% of new HIV diagnoses in the US, but are underrepresented in PrEP implementation efforts in the US.</p><p><strong>Methods: </strong>Fourteen semi-structured interviews were conducted with women (M = 32.1 years old, SD = 6.2 years) to understand their PrEP knowledge, clinical and system-level barriers, and supports needed to engage with PrEP. During data collection, the importance of sexual scripts, a social belief that women are heterosexual and 'pure', emerged as a major construct in shaping participants' health-care seeking experiences, regardless of their HIV risk perception or PrEP knowledge. A deductive-inductive thematic approach was used to further analyze this construct.</p><p><strong>Results: </strong>A majority of participants identified as a person of color: seven black women (50%), three multi-racial women (21%), and one Asian woman (7%). A majority of the participants had no experience with PrEP (57%); however, most participants had at least some knowledge of PrEP (72%). Sexual scripts surrounding women's sexuality, clinician priorities, and perceptions of who PrEP is \"for\" were reported as prominent barriers to PrEP prescription. Participants described clinical interactions that reinforced sexist and heteronormative beliefs and impeded access to necessary sexual health care. Participants emphasized that clinicians who approach sexual health conversations with an openness and non-judgmental demeanor can facilitate access to PrEP and improve overall sexual health.</p><p><strong>Conclusions: </strong>Findings highlight the need for concerted efforts to challenge sexual scripts in clinical settings and create safe environments where women can openly discuss sexual health.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Declining Fluoroquinolone Efficacy in Resistance-Guided Therapy for Mycoplasma genitalium: A Systematic Review and Meta-Analysis of Microbiological Cure.","authors":"Albanir Laier Bordignon, Felipe Lopes Grillo, André Rochinski Busanello, Newton Sérgio de Carvalho","doi":"10.1097/OLQ.0000000000002410","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002410","url":null,"abstract":"<p><p>Mycoplasma genitalium is an increasingly drug-resistant sexually transmitted infection, with widespread macrolide resistance rendering azithromycin frequently ineffective. Moxifloxacin, the main second-line treatment, is now threatened by fluoroquinolone resistance linked to the parC gene. Resistance-guided therapy, which tailors treatment to macrolide-resistance mutations detected after nucleic acid amplification testing, shows promise, but its pooled cure rate has not been quantified. Following a protocol registered in PROSPERO (CRD420251077720), we searched five databases for studies of resistance-guided therapy reporting cure (negative test-of-cure 14-90 days after treatment); 11 studies were eligible. Cure proportions were pooled with a random-effects Freeman-Tukey model with Hartung-Knapp adjustment and, as a co-primary approach, a generalized linear mixed model; we performed sensitivity analyses, a temporal meta-regression of moxifloxacin cure, and stratification by parC mutation. Pooled cure was 94.6% (95% confidence interval [CI] 92.4-96.4) and 93.9% (95% CI 91.7-95.5) across the two models, with no heterogeneity (I² = 0%) and robust in sensitivity analyses. However, moxifloxacin cure declined over time (odds ratio per calendar year 0.92; 95% CI 0.85-0.99; p = 0.033), driven by the parC S83I mutation (98% cure in wild-type versus 38% in mutants). In a modeled high-resistance Brazilian scenario (79% macrolide resistance), expected cure with empirical azithromycin fell to approximately 22%, versus approximately 93% with resistance-guided therapy. The evidence derives predominantly from a single center and a short-term surrogate outcome, with low-to-very-low certainty. Resistance-guided therapy achieves high short-term cure and should be prioritized over empirical therapy, yet its efficacy is time-limited and calls for parC-guided regimens as resistance evolves.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Syndrome in Adults with HIV on Antiretroviral Therapy: Risk Factors and a Predictive Model.","authors":"Xiangqing Wang, Pei Li, Xiao Dang, Jingjing Li, Wenjing Ma, Lu Ren, Yingying Ma","doi":"10.1097/OLQ.0000000000002413","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002413","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is common among people living with HIV, especially those receiving long-term antiretroviral therapy (ART). This study aimed to identify risk factors for MetS in adults with HIV receiving ART and to develop a predictive nomogram.</p><p><strong>Methods: </strong>This cross-sectional study included 1,135 adults with HIV receiving ART at Tangdu Hospital, Xi'an, China, between January 2022 and January 2025. MetS was defined using modified NCEP ATP III criteria. Sociodemographic, lifestyle, clinical, and laboratory data were collected. Logistic regression and LASSO-penalized regression were used to identify predictors. A nomogram was developed and internally validated.</p><p><strong>Results: </strong>The mean age was 39.49 ± 10.10 years, 54.4% of participants were male, and the mean BMI was 24.23 ± 3.72 kg/m². Overall, 315 participants (27.8%) met the criteria for MetS. Compared with those without MetS, participants with MetS were older, had higher BMI, and had longer ART duration (all P < 0.001). Current smoking, regular alcohol use, physical inactivity, and poor fruit/vegetable intake were more common in the MetS group (all P < 0.001). The final nomogram included age, smoking status, alcohol consumption, physical activity, dietary habits, BMI group, ART duration, ART regimen class, and viral suppression. It showed good discrimination, with an AUC of 0.898 in the training cohort and 0.881 in the validation cohort.</p><p><strong>Conclusions: </strong>MetS was common among adults with HIV receiving ART. The nomogram may support individualized metabolic risk stratification and help identify adults with HIV who may benefit from closer metabolic monitoring and targeted lifestyle assessment.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic resistance mutations in Mycoplasma genitalium and non-gonococcal urethritis treatment outcomes.","authors":"Nikki Adriaens, Sylvia M Bruisten, Brenda M Westerhuis, Alje P van Dam, Maarten F Schim van der Loeff, Tessa A Doelman, Luann Noordpool, Henry J C de Vries, Clarissa E Vergunst","doi":"10.1097/OLQ.0000000000002408","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002408","url":null,"abstract":"<p><strong>Background: </strong>In the Netherlands, Mycoplasma genitalium (MG) shows high macrolide resistance (75%) and increasing fluoroquinolone resistance (10%), limiting azithromycin and moxifloxacin efficacy. Despite high macrolide resistance, non-gonococcal urethritis (NGU) guidelines recommend delaying moxifloxacin until four weeks after azithromycin. This study evaluated microbiological and clinical cure of MG following sequential azithromycin and moxifloxacin treatment in relation to antibiotic resistance.</p><p><strong>Methods: </strong>Men with NGU at the Centre for Sexual Health Amsterdam underwent physical examination and urine testing. MG-positive participants were followed up to 6 weeks. All received azithromycin 1 g at baseline; moxifloxacin was administered at week 4 for persistent MG-NGU. Macrolide (23S rRNA, rplD, rplV) and fluoroquinolone (parC, parE, gyrA, gyrB) resistance mutations and mgpB genotypes were assessed using nanopore sequencing.</p><p><strong>Results: </strong>Among 30 MG-NGU cases, azithromycin achieved low microbiological cure, with 22 remaining positive at week 4. By week 6, 21 participants attended follow-up. Moxifloxacin was prescribed to 14 participants: 1 with persistent NGU and MG positivity, 5 with persistent NGU despite MG clearance, 3 with persistent MG without NGU, and 5 with resolution of both. Among the 7 untreated participants, 5 remained MG-positive with persistent NGU and 2 remained MG-positive without NGU. Symptoms generally improved despite persistent microbiological or clinical findings. ParC S83I mutations occurred in both successfully and unsuccessfully treated participants. ParE and gyrB mutations were less frequent and usually co-occurred with parC. Two persistent infections carried combined parC S83I, parE G492E, and gyrB R464K mutations.</p><p><strong>Conclusions: </strong>Sequential azithromycin and moxifloxacin achieved limited microbiological cure and NGU resolution. Symptom improvement despite persistent infection highlights discordance between microbiological and clinical outcomes. ParC S83I was common but did not consistently predict moxifloxacin failure. Persistent infections with combined parC, parE, and gyrB mutations suggest cumulative effects, requiring further studies.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between trauma and sexual health outcomes among transgender women in the US Deep South.","authors":"Olivia T Van Gerwen, Katelyn S Day, Kristal J Aaron, Hannah Lindl, Gabe H Miller, D Scott Batey, Bulent Turan, Christina A Muzny","doi":"10.1097/OLQ.0000000000002404","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002404","url":null,"abstract":"<p><p>Transgender women are disproportionately affected by sexually transmitted infections (STIs), likely shaped by trauma. In 105 participants, multiple trauma subtypes were linked to lower HIV pre-exposure prophylaxis awareness, lifetime STI history, and recent STI testing. Trauma may contribute to the ongoing STI burden in this population.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Same-Day, Direct HIV PrEP Dispensation on PrEP Initiation and Early Retention in a Sexual Health Clinic.","authors":"Nikhil Harikrishnan, Kaitlin A Zinsli, Christine M Khosropour, Julia C Dombrowski, Chase A Cannon","doi":"10.1097/OLQ.0000000000002406","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002406","url":null,"abstract":"<p><strong>Background: </strong>Daily oral pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV but remains underutilized in the United States. Various factors, including limited access, contribute to drop-offs across the PrEP care continuum. In 2021, Seattle-King County's sexual health clinic (SHC) introduced same-day, in-clinic dispensing of an initial bottle of oral emtricitabine/tenofovir disoproxil fumarate at no out-of-pocket cost as an alternative to electronic prescribing to external community pharmacies (e-prescribing).</p><p><strong>Methods: </strong>We conducted a retrospective observational study using routinely collected SHC data to identify patients who completed ≥1 initial PrEP visit from November 1, 2020, to May 30, 2023. Successful early PrEP retention was defined as an initial visit, a PrEP prescription within 14 days, and a follow-up visit within 6 months. We compared the proportion achieving early retention across three phases: Phase 1 (e-prescribing only), Phase 2 (transition period), and Phase 3 (same-day dispensing with some e-prescribing), using two-sample tests of proportions.</p><p><strong>Results: </strong>Of 917 eligible patients, 649 (70.8%) were successfully retained on PrEP; 25.0% were uninsured. Early retention was similar across phases: 71.9% (210/292) in Phase 1, 70.0% (194/277) in Phase 2, and 70.4% (245/348) in Phase 3. Compared with Phase 1, retention did not differ significantly in Phase 2 (P=0.62) or Phase 3 (P=0.67), nor by dispensing modality within Phases 2 and 3.</p><p><strong>Conclusions: </strong>In this urban SHC, early PrEP retention remained stable at approximately 70%. Same-day, in-clinic dispensing was not associated with improved early retention but may reduce barriers and delays, representing a feasible low-barrier delivery model in resourced SHCs.</p>","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148970476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unknown Duration, Uncertain Epidemiology: The Conundrum of High-Titer Unknown Duration or Late Syphilis.","authors":"Brittany Liebhard, Abigail Norris Turner, Khalil G Ghanem, William C Miller","doi":"10.1097/OLQ.0000000000002414","DOIUrl":"https://doi.org/10.1097/OLQ.0000000000002414","url":null,"abstract":"","PeriodicalId":21837,"journal":{"name":"Sexually transmitted diseases","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}